Skip to content

Progesterone Induced Blocking Factor Expression Levels in Endometrial Cancer Cells.

Determining Levels of Expression of Progesterone-Induced Blocking Factor in Endometrial Cancer Cells.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02852954
Enrollment
60
Registered
2016-08-02
Start date
2016-08-31
Completion date
2017-03-31
Last updated
2017-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progesterone Induced Blocking Factor in Endometrial Cancer

Keywords

Progesterone Induced Blocking Factor, Endometrial Cancer

Brief summary

Immune system suppression effect of Progesterone Induced Blocking Factor(PIBF), it could be questionable whether tumor cells express PIBF for escape of immune system. There are some studies in the literature that evaluate PIBF expression of different malign cells (e.g. glioblastoma multiforme as a malign central nerve system, leukemia, astrocytoma as a primary brain tumor, lung cancer and chorionic carcinoma). According to previous studies PIBF has been used as an anti-tumor immune suppressor by tumor cells. There is no data about the PIBF expression of endometrial tumor cells. Therefore, the investigators aim to determine the PIBF expression levels in the endometrial cancer cells.

Detailed description

This retrospective controlled study will be conducted at both Obstetrics and Gynecology clinics and Pathology clinics of Kayseri Training and Research Hospital. This study will be conducted with the use of formalin fixed paraffin embedded tissue blocks immunohistochemically to determine the PIBF expression levels in the samples. There are three groups in this study; endometrial cancer, endometrial hyperplasia and normal endometrium and each of the groups contained 20 paraffin embedded blocks provided form the Pathology clinic of Kayseri Training and Research Hospital archives.

Interventions

None listed

Sponsors

Kayseri Education and Research Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* diagnosed endometrial cancer * diagnosed endometrial hyperplasia

Exclusion criteria

* diagnosed cancer except endometrial cancer

Design outcomes

Primary

MeasureTime frame
Immunohistochemically Levels of PIBF in Endometrial Cancer Cells3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026